Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
TERMINATED
NCT00788125
PHASE1/PHASE2

Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors

Sponsor: City of Hope Medical Center

View on ClinicalTrials.gov

Summary

RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs in chemotherapy, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving dasatinib together with ifosfamide, carboplatin, and etoposide may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of dasatinib when given together with ifosfamide, carboplatin, and etoposide and to see how well they work in treating young patients with metastatic or recurrent malignant solid tumors.

Official title: Dasatinib With Ifosfamide, Carboplatin, Etoposide: A Pediatric Phase I/II Trial

Key Details

Gender

All

Age Range

1 Year - 25 Years

Study Type

INTERVENTIONAL

Enrollment

7

Start Date

2008-09-10

Completion Date

2022-07-30

Last Updated

2026-11-04

Healthy Volunteers

No

Interventions

DRUG

carboplatin

DRUG

dasatinib

DRUG

etoposide phosphate

DRUG

ifosfamide

GENETIC

microarray analysis

GENETIC

western blotting

OTHER

immunohistochemistry staining method

OTHER

laboratory biomarker analysis

PROCEDURE

therapeutic conventional surgery

RADIATION

radiation therapy

Locations (1)

City of Hope Medical Center

Duarte, California, United States